Royalty Pharma plc (RPRX)

Market Cap	22.83B
Revenue (ttm)	2.35B
Net Income (ttm)	764.96M
Shares Out	577.24M
EPS (ttm)	1.75
PE Ratio	22.58
Forward PE	7.83
Dividend	$0.94 (2.38%)
Ex-Dividend Date	Feb 20, 2026

Volume	1,941,339
Open	39.72
Previous Close	39.72
Day's Range	39.35 - 39.78
52-Week Range	29.66 - 41.70
Beta	0.42
Analysts	Strong Buy
Price Target	45.75 (+15.68%)
Earnings Date	Feb 10, 2026

About RPRX

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 16, 2020
• Employees: 99
• Stock Exchange: NASDAQ
• Ticker Symbol: RPRX
• Website: https://www.royaltypharma.com

Financial Performance

In 2024, Royalty Pharma's revenue was $2.26 billion, a decrease of -3.86% compared to the previous year's $2.35 billion. Earnings were $858.98 million, a decrease of -24.31%.

Analyst Summary

According to 4 analysts, the average rating for RPRX stock is "Strong Buy." The 12-month stock price target is $45.75, which is an increase of 15.68% from the latest price.

Price Target

$45.75

(15.68% upside)

Analyst Consensus: Strong Buy